Guard Therapeutics International AB (SE:GUARD)
:GUARD
GUARD Stock Chart & Stats
kr1.38
-kr0.80(-4.00%)
At close: 4:00 PM EST
kr1.38
-kr0.80(-4.00%)
Day’s Range― - ―
52-Week Rangekr1.10 - kr27.00
Previous CloseN/A
Volume1.94K
Average Volume (3M)44.15K
Market Cap
kr30.86M
Enterprise Value-kr18.97M
Total Cash (Recent Filing)kr100.48M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding20,167,631
10 Day Avg. Volume59,609
30 Day Avg. Volume44,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Financial DebtThe absence of debt materially lowers interest and refinancing burdens for a clinical-stage biotech. That structural balance-sheet strength preserves strategic optionality for R&D financing, reduces near-term default risk, and makes equity or partnership funding less pressured when raising future capital.
Cash Flows Align With Reported LossesConsistent alignment of free cash flow with reported losses implies limited accounting or non-cash distortions. This improves confidence in the quality of operating metrics, making forecast modeling and runway assessment more reliable for investors and management over the medium term.
Focused Clinical Strategy (AKI/renal)A clear, narrow therapeutic focus on AKI and renal conditions concentrates R&D efforts and expertise. That strategic clarity supports efficient trial design, targeted partnership discussions, and the potential to achieve niche leadership if clinical milestones are met, a durable advantage for a small biotech.
Bears Say
No Revenue, Persistent LossesNo revenue across multiple years and sustained net losses mean the company is fully pre-revenue and dependent on external funding. Without commercial cash flow, ongoing operations and development hinge on future financing or partnerships, creating a structural funding dependency risk.
Heavy, Volatile Cash BurnLarge, recurring negative operating and free cash flows (e.g., -109.4M in 2025) deplete resources and create a persistent need for fresh capital. The volatility and scale of burn shorten runway and raise the probability of dilutive financings or constrained program pacing over the medium term.
Weakened Balance Sheet And Declining EquityA rapidly shrinking asset and equity base reduces the balance-sheet cushion that absorbs losses and funds operations. Declining shareholders' equity and assets limit financial flexibility, worsen leverage metrics if debt is later taken, and increase sensitivity to funding disruptions.
GUARD FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was kr1.10 and its highest was kr27.00 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is kr30.86M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is May 13, 2026 which is in 47 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on Feb 20, 2026. The company reported -kr0.81 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.81.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -kr0.81 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in SE:GUARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―